COMPOSITIONS AND METHODS FOR TREATING OBESITY AND RELATED DISORDERS
First Claim
1. A composition for treating obesity or a related condition in a subject comprising:
- a first pharmaceutical agent and a second pharmaceutical agent, wherein the second pharmaceutical agent is a sympathomimetic agent and wherein the first pharmaceutical agent is an anti-epileptic agent, CB1 receptor antagonist, or a 5HT2C-selective serotonin receptor agonist.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention is drawn to combinations of pharmaceutical agents having similar chemical and/or pharmacological properties, wherein the combinations maximize the therapeutic effect of the drug while minimizing their adverse effects. The methods and compositions of the invention are particularly useful in the treatment of obesity and related conditions which involves treating a subject with a sympathomimetic agent (e.g., phentermine or a phentermine-like drug) or bupropion in combination with an anti-epileptic agent (e.g., topiramate, zonisamide), CB1 antagonists (e.g., rimonabant), or a 5HT2C-selective serotonin receptor agonist, (e.g., lorcaserin) for the treatment of obesity and related conditions. The invention also features kits for use in the practice of these novel therapies.
-
Citations
43 Claims
-
1. A composition for treating obesity or a related condition in a subject comprising:
- a first pharmaceutical agent and a second pharmaceutical agent, wherein the second pharmaceutical agent is a sympathomimetic agent and wherein the first pharmaceutical agent is an anti-epileptic agent, CB1 receptor antagonist, or a 5HT2C-selective serotonin receptor agonist.
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)
- 20. A method for treating obesity or a related condition in a subject comprising administering to the subject a first pharmaceutical agent and a second pharmaceutical agent, wherein the second pharmaceutical agent is a sympathomimetic agent and wherein the first pharmaceutical agent is an anti-epileptic agent, CB1 receptor antagonist, or a 5HT2C-selective serotonin receptor agonist.
-
42. A kit comprising a packaged combination of a first pharmaceutical agent and a second pharmaceutical agent, wherein the second pharmaceutical agent is a sympathomimetic agent and wherein the first pharmaceutical agent is an anti-epileptic agent, CB1 receptor antagonist, or a 5HT2C-selective serotonin receptor agonist and instructions for a patient to carry out drug administration to achieve weight loss, wherein the first and second pharmaceutical agents are present in separate and discrete dosage forms.
-
43. A kit comprising a sealed package of controlled release dosage forms each containing a first pharmaceutical agent and a second pharmaceutical agent, wherein the second pharmaceutical agent is a sympathomimetic agent and wherein the first pharmaceutical agent is an anti-epileptic agent, CB1 receptor antagonist, or a 5HT2C-selective serotonin receptor agonist, wherein the dosage forms provide for immediate release of the second pharmaceutical agent and delayed release of the first pharmaceutical agent.
Specification